Jesse Berry

Dr. Jesse Berry

Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2017 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
Jesse BerryJesse Berry
Jesse Berry
LXLiya Xu
Liya Xu
AMA. Linn Murphree
A. Linn Murphree
SKSubramanian Krishnan
Subramanian Krishnan
KSKevin Stachelek
Kevin Stachelek
JHJames Hicks
James Hicks
Retinoblastoma (Rb) is a primary pediatric ocular cancer and one of the first tumors to have a known genetic etiology.1-4 Most germline and sporadic forms of Rb develop in response to biallelic mutations in RB1 (phenotype OMIM 180200 and gene/locus OMIM 614041), the first molecularly defined tumor suppressor gene.2,4,5 The elucidation of this gene and study of Rb provided a firm foundation for the field of cancer genetics. In addition to having RB1 mutations, Rb tumors analyzed after enucleation demonstrate recurrent chromosomal copy number variation (eg, regions of chromosomal gains and losses).6 These chromosomal changes underlie many human cancers7 and are frequent secondary genomic events during Rb tumorigenesis and contribute to disease progression.8,9 Yet, it has not been possible to define the effects of these chromosomal changes on treatment response and the disease course in Rb due to lack of access to tumor DNA. This lack of access is because, unlike many cancers, biopsy of Rb is contraindicated because of risk of tumor seeding outside the eye, possibly leading to orbital relapse.10-16

1 November 2018 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
Jesse BerryJesse Berry
Jesse Berry
Liya XuLiya Xu
Liya Xu
IKIrsan Kooi
Irsan Kooi
AMA. Linn Murphree
A. Linn Murphree
RPRishvanth K. Prabakar
Rishvanth K. Prabakar
JHJames Hicks
James Hicks
Tumor-derived cell-free DNA (cfDNA) has biomarker potential; therefore, this study aimed to identify cfDNA in the aqueous humor (AH) of retinoblastoma eyes and correlate somatic chromosomal copy-number alterations (SCNA) with clinical outcomes, specifically eye salvage. AH was extracted via paracentesis during intravitreal injection of chemotherapy or enucleation. Shallow whole-genome sequencing was performed using isolated cfDNA to assess for highly recurrent SCNAs in retinoblastoma including gain of 1q, 2p, 6p, loss of 13q, 16q, and focal MYCN amplification. Sixty-three clinical specimens of AH from 29 eyes of 26 patients were evaluated; 13 eyes were enucleated and 16 were salvaged (e.g., saved). The presence of detectable SCNAs was 92% in enucleated eyes versus 38% in salvaged eyes (P = 0.006). Gain of chromosome 6p was the most common SCNA found in 77% of enucleated eyes, compared with 25% of salvaged eyes (P = 0.0092), and associated with a 10-fold increased odds of enucleation (OR, 10; 95% CI, 1.8–55.6). The median amplitude of 6p gain was 1.47 in enucleated versus 1.07 in salvaged eyes (P = 0.001). The presence of AH SCNAs was correlated retrospectively with eye salvage. The probability of ocular salvage was higher in eyes without detectable SCNAs in the AH (P = 0.0028), specifically 6p gain. This is the first study to correlate clinical outcomes with SCNAs in the AH from retinoblastoma eyes, as such these findings indicate that 6p gain in the aqueous humor is a potential prognostic biomarker for poor clinical response to therapy. Implications: The correlation of clinical outcomes and SCNAs in the AH identified in the current study requires prospective studies to validate these finding before SCNAs, like 6p gain, can be used to predict clinical outcomes at diagnosis. Mol Cancer Res; 16(11); 1701–12. ©2018 AACR.

19 September 2012 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
Jesse BerryJesse Berry
Jesse Berry
RJRima Jubran
Rima Jubran
JKJonathan W. Kim
Jonathan W. Kim
KWKenneth Wong
Kenneth Wong
SBSimon R. Bababeygy
Simon R. Bababeygy
AMA. Linn Murphree
A. Linn Murphree

21 September 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HLHong-Tao Li
Hong-Tao Li
Liya XuLiya Xu
Liya Xu
Daniel WeissenbergerDaniel Weissenberger
Daniel Weissenberger
MLMeng Li
Meng Li
WZWanding Zhou
Wanding Zhou
Jesse BerryJesse Berry
Jesse Berry
Retinoblastoma (RB) is a cancer that forms in the developing retina of babies and toddlers. The goal of therapy is to cure the tumor, save the eye and maximize vision. However, it is difficult to predict which eyes are likely to respond to therapy. Predictive molecular biomarkers are needed to guide prognosis and optimize treatment decisions. Direct tumor biopsy is not an option for this cancer; however, the aqueous humor (AH) is an alternate source of tumor-derived cell-free DNA (cfDNA). Here we show that DNA methylation profiling of the AH is a valid method to identify the methylation status of RB tumors. We identify 294 genes directly regulated by methylation that are implicated in p53 tumor suppressor (RB1, p53, p21, and p16) and oncogenic (E2F) pathways. Finally, we use AH to characterize molecular subtypes that can potentially be used to predict the likelihood of treatment success for retinoblastoma patients.

1 November 2019 in Genes
Verified
Journal Article
Open access
PDF file
Jesse BerryJesse Berry
Jesse Berry
APAshley Polski
Ashley Polski
WCWebster Cavenee
Webster Cavenee
TDThaddeus P. Dryja
Thaddeus P. Dryja
AFAlan Linn Murphree, MD, FACS
Alan Linn Murphree, MD, FACS
BGBrenda Gallie
Brenda Gallie
The RB1 gene is the first described human tumor suppressor gene and plays an integral role in the development of retinoblastoma, a pediatric malignancy of the eye. Since its discovery, the stepwise characterization and cloning of RB1 have laid the foundation for numerous advances in the understanding of tumor suppressor genes, retinoblastoma tumorigenesis, and inheritance. Knowledge of RB1 led to a paradigm shift in the field of cancer genetics, including widespread acceptance of the concept of tumor suppressor genes, and has provided crucial diagnostic and prognostic information through genetic testing for patients affected by retinoblastoma. This article reviews the long history of RB1 gene research, characterization, and cloning, and also discusses recent advances in retinoblastoma genetics that have grown out of this foundational work.

13 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Liya XuLiya Xu
Liya Xu
Mary KimMary Kim
Mary Kim
APAshley Polski
Ashley Polski
RPRishvanth K. Prabakar
Rishvanth K. Prabakar
LSLishuang Shen
Lishuang Shen
Jesse BerryJesse Berry
Jesse Berry
Because direct tumor biopsy is prohibited for retinoblastoma (RB), eye-specific molecular biomarkers are not used in clinical practice for RB. Recently, we demonstrated that the aqueous humor (AH) is a rich liquid biopsy source of cell-free tumor DNA. Herein, we detail clinically-relevant molecular biomarkers from the first year of prospective validation data. Seven eyes from 6 RB patients who had AH sampled at diagnosis and throughout therapy with ≥12 months of follow-up were included. Cell-free DNA (cfDNA) from each sample was isolated and sequenced to assess genome-wide somatic copy number alterations (SCNAs), followed by targeted resequencing for pathogenic variants using a RB1 and MYCN custom hybridization panel. Tumoral genomic information was detected in 100% of diagnostic AH samples. Of the seven diagnostic AH samples, 5/7 were positive for RB SCNAs. Mutational analysis identified RB1 variants in 5/7 AH samples, including the 2 samples in which no SCNAs were detected. Two eyes failed therapy and required enucleation; both had poor prognostic biomarkers (chromosome 6p gain or MYCN amplification) present in the AH at the time of diagnosis. In the context of previously established pre-analytical, analytical, and clinical validity, this provides evidence for larger, prospective studies to further establish the clinical utility of the AH liquid biopsy and its applications to precision oncology for RB.